HUP0400687A2 - Mycoplasma hyopneumoniae bacterin vaccine - Google Patents

Mycoplasma hyopneumoniae bacterin vaccine

Info

Publication number
HUP0400687A2
HUP0400687A2 HU0400687A HUP0400687A HUP0400687A2 HU P0400687 A2 HUP0400687 A2 HU P0400687A2 HU 0400687 A HU0400687 A HU 0400687A HU P0400687 A HUP0400687 A HU P0400687A HU P0400687 A2 HUP0400687 A2 HU P0400687A2
Authority
HU
Hungary
Prior art keywords
mycoplasma hyopneumoniae
hyopneumoniae bacterin
immunity
single dose
infection
Prior art date
Application number
HU0400687A
Other languages
Hungarian (hu)
Inventor
Hsien-Jue Chu
Wumin Li
Zhichang Xu
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22972978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0400687(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth filed Critical Wyeth
Publication of HUP0400687A2 publication Critical patent/HUP0400687A2/en
Publication of HUP0400687A3 publication Critical patent/HUP0400687A3/en
Publication of HU227431B1 publication Critical patent/HU227431B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya javított Mycoplasma hyopneumoniae bakterinvakcinakészítmény, amely előnyösen fertőzéssel szembeni immunitástbiztosít egyetlen dózis beadása után. A készítmény inaktiváltMycoplasma hyopneumoniae bakterint és adjuvánskeveréket tartalmaz,amelyek kombinálva immunitást biztosítanak Mycoplasma hyopneumoniae-fertőzés ellen egyetlen dózis beadása után, és Mycoplasmahyopneumoniae bakterinre specifikus immunválaszt váltanak ki,beleértve a sejtközvetített immunitást és helyi (szekretorikus IgA)immunitást. Egy előnyös megvalósítási mód szerint az adjuvánskeverékakrilsavpolimert, legelőnyösebben Carbopolt, és metabolizálható olaj,mint például egy vagy több telítetlen terilén szénhidrogén, előnyösenszkvalén és polioxietilén-polioxipropilén blokk-kopolimer, mintpéldául Pluronic< keverékét tartalmazza. A vakcinakészítmény adottesetben tartalmazhat tartósítószert, előnyösen timerozált és/vagyEDTA-t. ÓThe subject of the invention is an improved Mycoplasma hyopneumoniae bacterin vaccine preparation, which preferably provides immunity against infection after a single dose. The preparation contains inactivated Mycoplasma hyopneumoniae bacterin and adjuvant mixture, which in combination provide immunity against Mycoplasma hyopneumoniae infection after administration of a single dose and induce a specific immune response to Mycoplasma hyopneumoniae bacterin, including cell-mediated immunity and local (secretory IgA) immunity. According to a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably Carbopol, and a metabolizable oil, such as a mixture of one or more unsaturated terylene hydrocarbons, preferably squalene, and a polyoxyethylene-polyoxypropylene block copolymer, such as Pluronic<. The vaccine preparation may optionally contain a preservative, preferably thimerosal and/or EDTA. HE

HU0400687A 2000-12-19 2001-12-11 Mycoplasma hyopneumoniae bacterin vaccine HU227431B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25663700P 2000-12-19 2000-12-19
PCT/US2001/047865 WO2002049666A2 (en) 2000-12-19 2001-12-11 Mycoplasma hyopneumoniae bacterin vaccine

Publications (3)

Publication Number Publication Date
HUP0400687A2 true HUP0400687A2 (en) 2004-06-28
HUP0400687A3 HUP0400687A3 (en) 2004-10-28
HU227431B1 HU227431B1 (en) 2011-06-28

Family

ID=22972978

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400687A HU227431B1 (en) 2000-12-19 2001-12-11 Mycoplasma hyopneumoniae bacterin vaccine

Country Status (28)

Country Link
US (4) US20020131980A1 (en)
EP (1) EP1343525B1 (en)
JP (2) JP5074656B2 (en)
KR (1) KR100874119B1 (en)
CN (1) CN1296095C (en)
AR (1) AR033410A1 (en)
AT (1) ATE359813T1 (en)
AU (2) AU2002228993B2 (en)
BG (1) BG66213B1 (en)
BR (1) BRPI0116249B1 (en)
CY (1) CY1106669T1 (en)
CZ (1) CZ307075B6 (en)
DE (1) DE60127994T2 (en)
DK (1) DK1343525T3 (en)
ES (1) ES2283452T3 (en)
HK (1) HK1056513A1 (en)
HR (1) HRP20030585B1 (en)
HU (1) HU227431B1 (en)
ME (1) ME00570B (en)
MX (1) MXPA03005357A (en)
MY (1) MY129765A (en)
NZ (1) NZ526904A (en)
PL (1) PL211174B1 (en)
PT (1) PT1343525E (en)
RS (1) RS51536B (en)
TW (1) TWI308872B (en)
WO (1) WO2002049666A2 (en)
ZA (1) ZA200305545B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
GB0400264D0 (en) * 2004-01-07 2004-02-11 Polytherics Ltd Complexes
UA95602C2 (en) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Pcv2 immunogenic compositions and methods of producing such compositions
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
CN104474541B (en) 2005-12-29 2019-08-23 勃林格殷格翰动物保健美国有限公司 PCV2 immunogenic composition is used to mitigate the purposes of pig clinical symptoms
MX365868B (en) 2005-12-29 2019-06-18 Boehringer Ingelheim Vetmedica Inc Multivalent pcv2 immunogenic compositions and methods of producing such compositions.
US20100129397A1 (en) 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
EP3466442A1 (en) 2006-12-15 2019-04-10 Boehringer Ingelheim Vetmedica, Inc. Treatment of mda seropositive pigs with pcv2 antigen
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
ME01000B (en) 2007-11-06 2012-10-20 Zoetis Services Llc Mycoplasma hyopneumoniae avirulent-adjuvanted live vaccine
BRPI0907438A2 (en) 2008-01-23 2015-08-04 Boehringer Ingelheim Vetmed Immunogenic compositions for mycoplasma hyopneumoniae and pcv2 and methods for producing such compositions
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
CA2728735A1 (en) * 2008-06-25 2009-12-30 Braasch Biotech Llc Compositions and methods for enhanced somatostatin immunogenicity
ES2579935T3 (en) * 2009-05-19 2016-08-17 Bioproperties Pty Ltd Mycoplasma Hyopneumoniae temperature-sensitive vaccine strain and use thereof
KR102185682B1 (en) 2009-06-04 2020-12-11 고쿠리츠칸센쇼켄쿠죠 Vaccine for mycoplasma infection
AR078253A1 (en) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed METHODS TO REDUCE ANTIVIRICAL ACTIVITY IN PCV-2 COMPOSITIONS AND PCV-2 COMPOSITIONS WITH BETTER IMMUNOGENICITY
DK2475384T3 (en) * 2009-09-10 2016-10-24 Merial Inc NEW VACCINE FORMULATIONS COMPREHENSIVE saponin-CONTAINING ADJUVANTS
JP5815676B2 (en) 2010-04-30 2015-11-17 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド General-purpose vaccine against H5N1 series
US20150086587A1 (en) * 2012-03-28 2015-03-26 Kansas State University Research Foundation Vaccine adjuvant
UA114504C2 (en) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс PCV, MYCOPLASMA HYOPNEUMONIA AND PRRS COMBINED VACCINE
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (en) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс PCV AND MYCOPLASMA HYOPNEUMONIA COMBINED VACCINE
CN103623400B (en) * 2012-08-24 2016-08-17 普莱柯生物工程股份有限公司 Vaccine composition for resisting pig mycoplasma pneumonia and infectious pleuropneumonia and preparation method and preparation method
EP2938747B1 (en) 2012-12-28 2019-05-01 Boehringer Ingelheim Vetmedica GmbH Method of making a mycoplasma vaccine
BR112015015199B1 (en) * 2012-12-28 2022-09-06 Boehringer Ingelheim Vetmedica Gmbh IMMUNOGENIC COMPOSITION COMPRISING MYCOPLASM ANTIGENS AND USE
CN104338128B (en) * 2013-07-31 2017-09-05 普莱柯生物工程股份有限公司 A kind of vaccine combination and its preparation method and application
CN105658660A (en) 2013-10-02 2016-06-08 勃林格殷格翰动物保健公司 Pcv2 orf2 protein variant and virus like particles composed thereof
EP3454893A4 (en) * 2016-05-11 2020-01-01 Phibro Animal Health Corporation A composition comprising antigens and a mucosal adjuvant and a method for using
BR112020011041A2 (en) * 2017-12-04 2020-11-17 Intervet International B.V. vaccine against canine lyme disease
CN108324941A (en) * 2018-04-03 2018-07-27 林淑卿 Pig disease vaccine adjuvant and preparation method thereof
CN117100851A (en) * 2023-10-23 2023-11-24 成都依思康生物科技有限公司 Adjuvant, vaccine composition, and preparation method and application thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3790665A (en) 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA1267087A (en) 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
ES2052685T3 (en) 1987-03-17 1994-07-16 Akzo Nv METHOD TO PRODUCE A FREE ADJUVANT.
NZ226811A (en) * 1987-11-03 1991-06-25 Syntex Inc Adjuvant emulsion comprising a glycopeptide and non-toxic tetra-polyol or pop-poe block copolymer wherein oily particle size is less than 800am
US5240706A (en) 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
DE69128361T3 (en) 1990-05-29 2006-04-13 Wyeth Holdings Corp. VACCINE AGAINST PNEUMONIA IN PIGS AND METHOD FOR ITS MANUFACTURE
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5695769A (en) * 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
AU667858B2 (en) 1991-11-15 1996-04-18 Smithkline Beecham Corporation Gram-negative bacterial vaccines
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) * 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
JP3265095B2 (en) * 1993-11-19 2002-03-11 本田技研工業株式会社 Canister
DK0759780T3 (en) * 1994-05-10 2000-11-13 American Home Prod Enhanced modified live BRSV vaccine
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (en) * 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus antigen for the diagnosis of lung worm infestation and for vaccination
US5846735A (en) * 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
KR100615109B1 (en) * 1996-12-20 2006-08-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 USPA1 and USPA2 antigens of Moraxella catarrhalis
FR2775601B1 (en) * 1998-03-03 2001-09-21 Merial Sas RECOMBINANT LIVING VACCINES AND ADJUVANTS
US6342231B1 (en) * 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
US6632439B2 (en) * 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
AP2003002937A0 (en) * 2001-07-02 2003-12-31 Pfizer Prod Inc One dose vaccination with mycoplasma hyopneumoniae
EP1480619B1 (en) * 2002-03-07 2013-08-07 Biocompatibles UK Limited Drug carriers comprising amphiphilic block copolymers
ITMI20030269A1 (en) * 2003-02-14 2004-08-15 Advance Holdings Ltd CETYLPYRIDINE SALT OF AN ANTI-INFLAMMATORY AGENT
US8052762B1 (en) * 2010-09-02 2011-11-08 Kelly Van Gogh, LLC Compositions for dyeing keratin-containing fibers

Also Published As

Publication number Publication date
US20120213816A1 (en) 2012-08-23
PL211174B1 (en) 2012-04-30
BG66213B1 (en) 2012-05-31
CN1296095C (en) 2007-01-24
ZA200305545B (en) 2004-10-18
BG107898A (en) 2004-08-31
JP2009073855A (en) 2009-04-09
PT1343525E (en) 2007-07-12
DE60127994D1 (en) 2007-05-31
HU227431B1 (en) 2011-06-28
ME00570A (en) 2011-12-20
WO2002049666A2 (en) 2002-06-27
HK1056513A1 (en) 2004-02-20
DK1343525T3 (en) 2007-06-04
US8187588B2 (en) 2012-05-29
US9238065B2 (en) 2016-01-19
US20070020296A1 (en) 2007-01-25
DE60127994T2 (en) 2008-01-17
CY1106669T1 (en) 2012-05-23
AR033410A1 (en) 2003-12-17
BR0116249A (en) 2004-03-02
US20020131980A1 (en) 2002-09-19
YU49303A (en) 2006-08-17
AU2899302A (en) 2002-07-01
ATE359813T1 (en) 2007-05-15
WO2002049666A3 (en) 2003-02-06
BRPI0116249B1 (en) 2016-06-14
NZ526904A (en) 2005-07-29
TWI308872B (en) 2009-04-21
ES2283452T3 (en) 2007-11-01
MY129765A (en) 2007-04-30
ME00570B (en) 2011-12-20
US7666439B2 (en) 2010-02-23
KR100874119B1 (en) 2008-12-15
EP1343525A2 (en) 2003-09-17
EP1343525B1 (en) 2007-04-18
US20100119471A1 (en) 2010-05-13
MXPA03005357A (en) 2003-10-06
HRP20030585B1 (en) 2008-03-31
JP5074656B2 (en) 2012-11-14
CZ307075B6 (en) 2018-01-03
AU2002228993B2 (en) 2006-06-29
KR20030065556A (en) 2003-08-06
HRP20030585A2 (en) 2005-06-30
HUP0400687A3 (en) 2004-10-28
CZ20031721A3 (en) 2004-04-14
RS51536B (en) 2011-06-30
CN1489472A (en) 2004-04-14
PL363220A1 (en) 2004-11-15
JP2004518655A (en) 2004-06-24

Similar Documents

Publication Publication Date Title
HUP0400687A2 (en) Mycoplasma hyopneumoniae bacterin vaccine
RS99704A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
IS4518A (en) New vaccine formulation
ES2149361T3 (en) LIVING VACCINE MODIFIED AGAINST BRSV, IMPROVED.
DE69527202D1 (en) Protein-like adjuvants
PT865297E (en) COMPOSITIONS OF VACCINES FOR INTRANASAL ADMINISTRATION UNDERSTANDING QUITOSAN AND ITS USES
LU91778I2 (en) Menveo - meningococcal vaccine groups A, C, W135 and Y conjugate.
NO20023935L (en) New, non-antigenic mucosal adjuvant formulation that modulates the effects of substances including vaccine antigens in contact with mucosal body surfaces
WO2004026024A3 (en) Vaccine compositions and adjuvant
BR0111834A (en) Adjuvant and immunogenic compositions, and method for eliciting an immune response to an antigen
DE60226175D1 (en) MYCOBACTERIAL VACCINE
BR0112792A (en) Bacterin, vaccine preparation, and methods for protecting a susceptible swine against colonization or infection of a mycoplasma hyopneumoniae and inducing an immune response in a susceptible swine against mycoplasmic pneumonia caused by a mycoplasma hyopneumoniae
DK0682950T3 (en) Mucosal administration of pneumococcal antigens
DK0757556T3 (en) Borrelia Burgdorferi bacterium
HK1025220A1 (en) Novel saponin compositions and uses thereof
TH64293A (en) Mycoplasma, hyaluronic acid Improved Bacteria vaccine

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ZOETIS W LLC, US

Free format text: FORMER OWNER(S): WYETH, US

GB9A Succession in title

Owner name: ZOETIS SERVICES LLC, US

Free format text: FORMER OWNER(S): WYETH, US; ZOETIS W LLC, US

FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): LENGYEL ZSOLT, DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

FH92 Termination of representative

Representative=s name: LENGYEL ZSOLT, DANUBIA SZABADALMI ES VEDJEGY I, HU

HC9A Change of name, address

Owner name: ZOETIS SERVICES LLC, US

Free format text: FORMER OWNER(S): WYETH, US; ZOETIS SERVICES LLC, US; ZOETIS W LLC, US